LIVECAST Markets Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Live News EQUITY FLASH L impact Oct 02, 2026, 07:29 PM UTC

UBS Maintains Buy on PepsiCo

UBS has maintained its Buy rating on PepsiCo.

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

PEP

Related stories

Global market picture: S&P 500 +0.15%, Nasdaq 100 +0.33%; EUR/USD +0.03%, WTI -0.04% Global market picture. US index futures: S and P futures is up 0.15 percent, Nasdaq futures is up 0.33 percent, Dow futures is up 0.1 percent and Russell futures is up 0.22 percent M impact | EQUITY | Oct 04, 2026, 11:30 PM UTC Schneider Electric Nears Deal To Acquire Software Group Ptc For $20 Billion Schneider Electric is nearing a deal to acquire software group PTC for approximately $20 billion, according to a source familiar with the matter. H impact | EQUITY | Oct 04, 2026, 11:02 PM UTC Global market picture: S&P 500 +0.14%, Nasdaq 100 +0.32%; EUR/USD +0.17%, WTI -0.09% Global market picture. US index futures: S and P futures is up 0.14 percent, Nasdaq futures is up 0.32 percent, Dow futures is up 0.12 percent and Russell futures is up 0.25 percen M impact | EQUITY | Oct 04, 2026, 11:00 PM UTC Alice Queen Seeks Trading Halt M impact | EQUITY | Oct 04, 2026, 10:36 PM UTC Global market picture: S&P 500 +0.1%, Nasdaq 100 +0.21%; EUR/USD +0.16%, WTI +0.34% Global market picture. US index futures: S and P futures is up 0.1 percent, Nasdaq futures is up 0.21 percent, Dow futures is up 0.11 percent and Russell futures is up 0.18 percent M impact | EQUITY | Oct 04, 2026, 10:30 PM UTC CSL inks $1.6B rare disease drug deal with Alentis Therapeutics CSL has entered into an agreement with Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal potentially worth up to $1.6 bill M impact | EQUITY | Oct 04, 2026, 10:09 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.